Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$12.2MCash on Hand
14.2mo Cash Runway
Follow ASBP by emailGet an email when ASBP pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ASBP, unsubscribe in one click. Privacy
🧪 Trial & FDA Catalysts
Oct 2025 · N/A · Results Expected · A Replicate Crossover Trial on Nutritional Supplementation in Association Football (Soccer Registry primary completion date, not a results date
Mar 2018 · Phase 4 · Results Expected · A Pilot Investigation Detecting Cryoablation Scar by 3D Late Gadolinium Enhancement Registry primary completion date, not a results date
Jun 2015 · N/A · Results Expected · Pivotal Aspiration Therapy With Adjusted Lifestyle Therapy Study Registry primary completion date, not a results date
Sep 2013 · Phase 4 · Results Expected · Effectiveness Study of Single Photon Emission Computed Tomography (SPECT) Versus Positron Registry primary completion date, not a results date
Jan 2012 · N/A · Results Expected · Efficiency and Outcomes of Stress-Only Anger and D-SPECT Stress-Only SPECT MPI Registry primary completion date, not a results date
Feb 2009 · N/A · Results Expected · Tongue Advancement for Obstructive Sleep Apnea Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
ASBP holds $12.2M in cash and short-term investments (as of Jun 30, 2026) and burns about $2.6M/quarter from operations,
an estimated runway of 14.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:8 · Low
Cash runway 14 months +18
Raised after last reported balance sheet (Aug 2026) -10
Share count 1,402,557 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full ASBP picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ASBP and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.